AGIOS PHARMACEUTICALS, INC. Increase (Decrease) in Contract with Customer, Liability
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-04.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2023-05-04
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2022-03-31 was $2.50M.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2021-03-31 was $0.00.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month |
|---|---|
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 |
| 2022-03-31 | $2.50M 10-Q · filed 2023-05-04 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |